Announcements Trials
Browse Landscape

Phase

Phase 1 22Phase 1/2 3Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 210Cyclophosphamide 122Nivolumab 109Carboplatin 92fludarabine 81Gemcitabine 77Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 53Ipilimumab 50Temozolomide 45Docetaxel 42Azacitidine 42Pemetrexed 41Lenalidomide 41Oxaliplatin 40Rituximab 39Radiotherapy 39Fluorouracil 39Cetuximab 37durvalumab 36Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × poly ICLC × 1 year × Clear all
NCT03789097 2026-05-22

Vaccination With Flt3L, Radiation, and Poly-ICLC

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT06614140 2026-04-22

Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

Seqker Biosciences, Inc.

Phase 1/2 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

NCT06782932 2025-12-03

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Recruiting
38 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡